Mayne Pharma Group Stock Buy Hold or Sell Recommendation
| MAYNF Stock | USD 3.10 0.10 3.33% |
Assuming the 90 days horizon and your complete indifference towards market risk, our recommendation regarding Mayne Pharma Group is 'Strong Buy'. Macroaxis provides Mayne Pharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding MAYNF positions.
Check out Mayne Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Mayne and provide practical buy, sell, or hold advice based on investors' constraints. Mayne Pharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Mayne |
Execute Mayne Pharma Buy or Sell Advice
The Mayne recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Mayne Pharma Group. Macroaxis does not own or have any residual interests in Mayne Pharma Group or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Mayne Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Market Performance | Insignificant | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Mayne Pharma Trading Alerts and Improvement Suggestions
| Mayne Pharma Group had very high historical volatility over the last 90 days | |
| Mayne Pharma Group has high likelihood to experience some financial distress in the next 2 years | |
| Mayne Pharma Group has accumulated 413.67 M in total debt with debt to equity ratio (D/E) of 0.74, which is about average as compared to similar companies. Mayne Pharma Group has a current ratio of 0.82, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Mayne Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Mayne Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mayne Pharma Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mayne to invest in growth at high rates of return. When we think about Mayne Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 423.92 M. Net Loss for the year was (263.34 M) with profit before overhead, payroll, taxes, and interest of 171.03 M. | |
| Mayne Pharma Group has accumulated about 98.01 M in cash with (7.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. | |
| Roughly 23.0% of Mayne Pharma outstanding shares are owned by corporate insiders |
Mayne Pharma Returns Distribution Density
The distribution of Mayne Pharma's historical returns is an attempt to chart the uncertainty of Mayne Pharma's future price movements. The chart of the probability distribution of Mayne Pharma daily returns describes the distribution of returns around its average expected value. We use Mayne Pharma Group price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Mayne Pharma returns is essential to provide solid investment advice for Mayne Pharma.
| Mean Return | 0.25 | Value At Risk | -4.76 | Potential Upside | 4.94 | Standard Deviation | 4.18 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Mayne Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Mayne Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Mayne Pharma or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Mayne Pharma's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Mayne pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.13 | |
β | Beta against Dow Jones | 1.02 | |
σ | Overall volatility | 4.25 | |
Ir | Information ratio | 0.03 |
Mayne Pharma Volatility Alert
Mayne Pharma Group exhibits very low volatility with skewness of 4.35 and kurtosis of 30.47. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Mayne Pharma's pink sheet risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Mayne Pharma's pink sheet price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Mayne Pharma Fundamentals Vs Peers
Comparing Mayne Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Mayne Pharma's direct or indirect competition across all of the common fundamentals between Mayne Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Mayne Pharma or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Mayne Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Mayne Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Mayne Pharma to competition |
| Fundamentals | Mayne Pharma | Peer Average |
| Return On Equity | -0.41 | -0.31 |
| Return On Asset | -0.0328 | -0.14 |
| Profit Margin | (0.62) % | (1.27) % |
| Operating Margin | (0.17) % | (5.51) % |
| Current Valuation | 448.85 M | 16.62 B |
| Shares Outstanding | 1.74 B | 571.82 M |
| Shares Owned By Insiders | 22.62 % | 10.09 % |
| Shares Owned By Institutions | 18.64 % | 39.21 % |
| Price To Earning | 11.25 X | 28.72 X |
| Price To Book | 0.73 X | 9.51 X |
| Price To Sales | 0.65 X | 11.42 X |
| Revenue | 423.92 M | 9.43 B |
| Gross Profit | 171.03 M | 27.38 B |
| EBITDA | (104.64 M) | 3.9 B |
| Net Income | (263.34 M) | 570.98 M |
| Cash And Equivalents | 98.01 M | 2.7 B |
| Cash Per Share | 0.06 X | 5.01 X |
| Total Debt | 413.67 M | 5.32 B |
| Debt To Equity | 0.74 % | 48.70 % |
| Current Ratio | 0.84 X | 2.16 X |
| Book Value Per Share | 0.32 X | 1.93 K |
| Cash Flow From Operations | (7.21 M) | 971.22 M |
| Earnings Per Share | (0.03) X | 3.12 X |
| Number Of Employees | 31 | 18.84 K |
| Beta | 1.0 | -0.15 |
| Market Capitalization | 235.41 M | 19.03 B |
| Total Asset | 1.29 B | 29.47 B |
| Annual Yield | 0.20 % | |
| Net Asset | 1.29 B |
Mayne Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Mayne . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Mayne Pharma Buy or Sell Advice
When is the right time to buy or sell Mayne Pharma Group? Buying financial instruments such as Mayne Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Mayne Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Moderate Funds Thematic Idea Now
Moderate Funds
Funds or Etfs that combine stocks, bonds and money market instruments to get modest capital appreciation over time. The Moderate Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Moderate Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Mayne Pink Sheet
Mayne Pharma financial ratios help investors to determine whether Mayne Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mayne with respect to the benefits of owning Mayne Pharma security.